Veeva Announces eSource Application for Research Sites to Eliminate Paper and Streamline Clinical Trial Data Flow
MWN-AI** Summary
Veeva Systems has officially announced the launch of its new eSource application, designed to revolutionize the data collection process at clinical trial research sites by eliminating paper and streamlining data flow. The Veeva eSource, part of the Veeva SiteVault platform, aims to significantly reduce manual processes and enhance data quality during clinical trials.
The application addresses common challenges faced by research sites, such as duplicate data entry and the burdensome transfer of data between Electronic Health Records (EHR) and Electronic Data Capture (EDC) systems. With its direct data capture features, the eSource application allows for intuitive digital data collection, minimizing the time spent on programming and transferring information. Alisha Garibaldi, CEO of Skylight Health Research, highlighted the efficiency of the new system, emphasizing that it reduces errors and allows clinical staff to focus more on patient interactions.
One of the key features of Veeva eSource is its integration capabilities. The application allows seamless transfers of patient data from EHR systems directly into eSource, and from there to EDC systems, thus streamlining the entire data flow. By eliminating the need for source data verification (SDV), the solution not only reduces the workload for sponsors but also enhances overall data integrity.
Overall, Veeva eSource represents a critical advancement in the clinical trials landscape, aiming to simplify and standardize processes for sponsors and research sites alike. Scheduled for early adopter availability in late 2026, this innovative technology is poised to improve the efficiency of clinical trials significantly while enhancing the experience for both patients and researchers. As Veeva continues to innovate in the life sciences industry, their commitment to enhancing clinical operations remains steadfast.
MWN-AI** Analysis
Veeva Systems’ recent announcement regarding its eSource application marks a significant advancement in the clinical trial landscape, promising enhanced efficiency and data integrity. As a financial analyst, it’s crucial to interpret how this innovation will impact Veeva's market performance and the broader life sciences sector.
The introduction of Veeva eSource aims to eliminate paper-based processes while integrating Electronic Health Records (EHR) with Electronic Data Capture (EDC) systems. This streamlined flow of trial data can potentially decrease manual entry errors, reduce data verification workloads, and accelerate clinical trial timelines. With greater efficiency, research sites can allocate more resources directly to patient care—aligning with the industry’s growing focus on patient-centric trials.
Investors should consider the competitive advantages that Veeva eSource offers. Its integration capabilities could enhance customer retention and attract new clients seeking to modernize their data management systems. The application’s open API ensures adaptability across existing EDC systems, catering to a broader market. Veeva's strong customer base, consisting of large biopharmaceutical companies and emerging biotechs, positions it well to capitalize on this opportunity.
However, it’s crucial to remain cautious. While the potential for market enhancement is substantial, Veeva must navigate challenges, including regulatory hurdles and the need for upfront investment from research sites to adopt this new technology. Additionally, competition in the clinical trial management space is strong, and Veeva will need to continuously innovate to stay ahead.
In conclusion, Veeva’s eSource initiative represents a pivotal moment for clinical trials, significantly improving efficiency and quality. Investors should view this development as a positive indicator of Veeva’s growth potential but remain mindful of the operational challenges ahead. A close watch on adoption rates and client feedback post-launch will be essential to gauge the long-term impact on Veeva’s financial health and market position.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Frees sites from duplicate data entry and connects EHR and EDC for higher quality trial data, faster
PLEASANTON, Calif., Jan. 29, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva eSource, a new Veeva SiteVault application designed to significantly reduce manual clinical trial processes and increase data quality. Veeva eSource will eliminate paper at the site through a direct data capture application and streamline data through EDC integration, and EHR to EDC transfer.
"I'm excited to see Veeva eSource in action; although there are other options in use by sites, traditional eSource is still incredibly time-consuming to program, complete, and transfer data from eSource to EDC," said Alisha Garibaldi, CEO, Skylight Health Research. "A seamless flow of data from Veeva eSource to EDC will reduce errors, minimize QC processing, and allow us to spend more time where it matters – with our patients."
With Veeva eSource, clinical trial data flows from site to sponsor with less effort through:
- Electronic Health Record (EHR) Integration: Transfers relevant patient data into eSource, then on to EDC. Eliminating the duplicate data capture happening in EDC today eases the burden on sites and patients.
- Direct Trial Data Capture Application: A simple, intuitive application that allows sites to collect trial data digitally, rather than on paper. Works alongside Veeva SiteVault CTMS, so that the site and patient can have one cohesive experience for the patient's journey in a trial.
- EDC Integration: Automates the flow of patient data from eSource to Veeva EDC, reducing latency and the risk of errors. The bidirectional integration also delivers the study protocol from EDC to eSource so sites can easily create forms that align with the study design. Veeva eSource's open API enables connection to any EDC system.
- Eliminates SDV: By collecting and using source data (versus transcribed data), Veeva eSource eliminates the need for laborious sponsor work for source data verification (SDV), freeing up time for sponsor staff to spend more effectively with the site.
"For the first time, we are connecting data and processes to enable straight-through clinical data flow from site to sponsor," said Jim Reilly, president of Veeva Development Cloud. "It is a major step toward our vision to simplify, standardize, and connect clinical trials for higher efficiency and a better experience for sponsors, sites, and patients."
"Veeva eSource advances our goal of delivering significant efficiency and simplicity for clinical trial sites," said Nick Frenzer, general manager of Veeva site solutions. "By delivering eSource, we can complete the picture to provide integrated data transparency across a site to improve trials."
Veeva eSource is part of the Veeva SiteVault platform and requires SiteVault CTMS at the site to simplify and streamline the visit experience for the site and patient. Veeva eSource is planned for early adopter availability in the second half of 2026.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.
Contact: | |
Deivis Mercado | Jeremy Whittaker |
Veeva Systems | Veeva Systems |
925-226-8821 | +49-695-095-5486 |
SOURCE Veeva Systems
FAQ**
How does Veeva eSource by Veeva Systems Inc. Class A VEEV ensure a seamless data flow from Electronic Health Records to Electronic Data Capture systems, and what benefits does this integration provide for clinical trial efficiency?
In what ways will Veeva eSource eliminate the need for manual data entry and source data verification, and how might this impact operational costs for research sites utilizing Veeva Systems Inc. Class A VEEV?
Can you elaborate on the anticipated market response to the early adopter availability of Veeva eSource in the second half of 2026, particularly for stakeholders in Veeva Systems Inc. Class A VEEV?
What are the potential risks and benefits associated with implementing Veeva eSource within clinical trials, given the context of Veeva Systems Inc. Class A VEEV’s commitment to innovation and customer success?
**MWN-AI FAQ is based on asking OpenAI questions about Veeva Systems Inc. Class A (NYSE: VEEV).
NASDAQ: VEEV
VEEV Trading
-1.42% G/L:
$184.92 Last:
519,564 Volume:
$189.69 Open:
